Virax aims to raise $3.85m after NIH disappointment
28 November, 2005 by Helen SchullerMelbourne immunotherapy developer Virax Holdings (ASX:VHL) has lodged a prospectus to raise AUD$3.85 million through a rights issue for the further development of its HIV therapeutic vaccine VIR201 following its unsuccessful bid for US NIH funding.
Epitan CEO replaced, appoints CSO
28 November, 2005 by Ruth BeranMelbourne-based Epitan's (ASX:EPT, ADR:EPTNY, XETRA:UR9) CEO Iain Kirkwood has been replaced by Dr Philippe Wolgen, effective immediately.
Cambridge research delves into memory
28 November, 2005 by Ruth BeranAnimals as diverse as sea slugs, fruit flies, mice and humans can learn. But how memories are stored in the brain and then retrieved is still a mystery, and Australian researcher Prof Seth Grant is trying to solve it.
APIA to broadcast live heart disease cases
25 November, 2005 by Helen SchullerCardiologists and medical professionals will witness the biggest heart disease live case demonstration in Australian history at the inaugural Asia-Pacific Interventional Advances Conference (APIA), taking place 29 November to 2 December in Newcastle.
Direct Capital acquires 51 per cent of New Zealand Pharmaceuticals
25 November, 2005 by Helen SchullerNew Zealand based VC Direct Capital has acquired a shareholding of 51 per cent in New Zealand Pharmaceuticals (NZP), which produces specialty chemicals for pharmaceutical and biotechnology companies.
Lack of understanding is holding back biotech: IPTA
25 November, 2005 by Helen SchullerA survey of biotechnology patent attorneys has indicated that there is a lack of knowledge within the general population about what biotechnology encompasses and there are misconceptions regarding the patenting process.
Further extensions sought in GTG/Applera dispute
25 November, 2005 by Graeme O'NeillMelbourne gene-test company Genetic Technologies (ASX: GTG; NASDAQ: GENE) US rival Applera Technologies have sought additional time from the US District Court of Northern California to resolve the long-running licensing dispute between the companies.
CollTech granted patent
25 November, 2005 by Ruth BeranPerth collagen purification company CollTech (ASX:CAU) has been granted a patent by the Australian Patents Office.
Leading anti-GM figure to tour Australia
24 November, 2005 by Graeme O'NeillAnti-GM NGO, the Australian GeneEthics Network, is hosting an Australian speaking tour by American Dr Chuck Benbrook, a prominent organic-food advocate and bete noire of genetically modified agriculture.
South Africa embracing biotech crops
24 November, 2005 by Graeme O'NeillWhile commercialisation of biotech crops in Australia remains frozen by state moratoriums, South African farmers are following their peers in China, India and South American nations in enthusiastically embracing the new age of agriculture, according to a South African industry leader.
Dynamic Hearing signs agreement with House Ear Institute
23 November, 2005 by Ruth BeranMelbourne-based biomedical company Dynamic Hearing has signed an agreement with the House Ear Institute (HEI) to develop and commercialise the US-based non-profit organisation's patented feedback cancellation technology for use in hearing aids and auditory implants.
AusBiotech, South Korea sign agreement
23 November, 2005 by Iain ScottAusBiotech and its South Korean equivalent, the Bioindustry Association of Korea (BAK), have signed an agreement that they hope will lead to a stronger relationship between the two countries' biotech industries.
BioProspect to raise AUD$1.95m
22 November, 2005 by Helen SchullerBrisbane natural pesticide developer BioProspect (ASX:BPO) is planning to raise AUD$1.95 million via a share placement and rights issue.
TetraQ forms strategic alliance with US company
22 November, 2005 by Ruth BeranUniversity of Queensland based contract research organisation TetraQ has formed a strategic alliance with Californian-based regulatory and product development consulting firm Ground Zero Pharmaceuticals (GZP).
CyGenics plans Cordlife listing in Asia
22 November, 2005 by Helen SchullerCell therapy company CyGenics (ASX:CYN) plans to investigate the possible listing of its tissue banking business, predominantly held under its subsidiary, CordLife, on a yet to be determined key Asian stock exchange.
